Strategy

Scrutiny of pharmaceutical promotion and gifts to practitioners has intensified, with more states enacting reporting requirements. In May, the federal government passed the Physician Payment Sunshine Act. What kind of impact is all this having on meetings and physician attendance?

Berwick's mission: To successfully translate the new healthcare bill into practice.

It's back to the future in Pharm Exec's second-annual review of industry prospects in the IMS "Pharmerging 17"

To shed some light on China's potential, Pharm Exec sat down with Peter Young, President and Managing Partner of Young & Partners, who recently met with government and industry officials to review the investment and M&A climate for medicines.

Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented.

John Castellani received the nod from PhRMA on Tuesday to take over the role of president and CEO in September.

As Europe sets the pace in slashing drug prices to meet austerity goals industry is seeking fresh ways to control the fallout. Will more dialogue be enough?

Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters-and how they plan to lead the industry through the turbulent times ahead.

Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?

Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline.

Lewis Morris, top lawyer in HHS's office of inspector general, explains his new move to target pharma execs for serious and ongoing healthcare fraud.

Pfizer's Specialty Product Business Unit leader discusses his vision for the drug giant's specialty business; now the largest in the industry.

The Orphan Drug Act of 1983 has been a roaring success. So why is everybody trying to mess with it?

How will US healthcare reform affect drug pricing, revenue, and compliance?

After a year of losses, the biologics sector got a big boost in profits in 2009. However, with companies holding back on R&D spending and venture capitalists becoming more frugal, can the industry possibly see further growth?

As head of GSK's North American pharma, Deirdre Connelly has the daunting challenge of trying to turn around the sluggish US market. If she succeeds, Connelly may find herself auditioning as the first female Big Pharma CEO.

Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales.

Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.

A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity?

Pricing, promotion, and the unfinished story of healthcare reform dominated the news last year.

In a digital world, vast quantities of data at hand are a powerful asset. Managing that information is key to seizing competitive advantage.

Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect?

Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?

The company released its numbers for 4Q '09, but is still hunting for more annual savings, which could come in the form of up to 15,000 job cuts.

Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast.

As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.

Sales compensation practices are due for an overhaul in 2010.

In a disruptive era of change, old-fashioned intuition still counts.